In specific, miR-19 has been proven sufficient to promote leukemogenesis in Notch1-induced T-ALL in vivo and to influence cell cycle progression by targeting cyclin-dependent kinase inhibitor CDKN1A (p21), whereas inhibition of miR-19b seems to lead Jurkat cells to increased apoptosis [193,194]. Here, CDKN1A is linked to acute lymphoblastic leukemia.